[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-340251-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-340251-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","loss-of-dock2-potentiates-inflammatory-bowel-diseaseassociated-colorectal-cancer-via-immune-dysfunction-and-ifn-induction-of-ido1-expression","Loss of DOCK2 potentiates Inflammatory Bowel Disease–associated colorectal cancer via immune dysfunction and IFNγ induction of IDO1 expression","","Inflammatory Bowel Disease–associated colorectal cancer (IBD-CRC) is a serious colonic complication of IBD, but its mechanisms remain less defined than sporadic colorectal cancer. This study investigates Dock2, mutated in ~10% of IBD-CRC, using a genetically engineered IBD-CRC mouse model. Whole-body Dock2 loss increases tumorigenesis through immune dysregulation, elevating IFNγ-associated genes including IDO1, driven by enhanced IFNγ production and T-cell infiltration, and delaying disease with IDO1 inhibition.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/loss-of-dock2-potentiates-inflammatory-bowel-diseaseassociated-colorectal-cancer-via-immune-dysfunction-and-ifn-induction-of-ido1-expression/340251/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/loss-of-dock2-potentiates-inflammatory-bowel-diseaseassociated-colorectal-cancer-via-immune-dysfunction-and-ifn-induction-of-ido1-expression/340251.png","ImageObject",300,407,{"name":42,"@type":43},"Sage","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main finding about DOCK2 in IBD-associated colorectal cancer?","Question",{"text":63,"@type":64},"Whole-body loss of Dock2 increases tumorigenesis by causing immune dysregulation in a DSS-induced IBD-CRC mouse model.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does Dock2 deficiency affect IFNγ and IDO1 expression?",{"text":68,"@type":64},"Dock2-deficient tumors show increased IFNγ-associated gene expression, including elevated IDO1, alongside increased tryptophan metabolism.",{"name":70,"@type":61,"acceptedAnswer":71},"What role do T cells play in the Dock2-related pathway?",{"text":72,"@type":64},"Dock2 loss is linked to increased IFNγ production in T-cell populations that infiltrate tumors, promoting IDO1 expression in tumor epithelial cells.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},340251,1790817077,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","[www.nature.com/onc](www.nature.com/onc Oncogene)[ Oncogene](www.nature.com/onc Oncogene)  \nARTICLE OPEN   \nLoss of DOCK2 potentiates Inﬂammatory Bowel Disease–associated colorectal cancer via immune dysfunction and IFNγ induction of IDO1 expression  \nAntonia M. D. Churchhouse 1, Caroline V. Billard1, Toshiyasu Suzuki2,3, Sebastian Ö . G. Pohl 1, Nora J. Doleschall 1, Kevin Donnelly1, Colin Nixon 2, Mark J. Arends 1, Shahida Din 4, Kathryn Kirkwood5, Jair Marques Junior 1, Alex Von Kriegsheim 1,  \nSeth B. Coffelt 2,3 and Kevin B. Myant 1 ✉  \n© The Author(s) 2024  \n\n|  | Inﬂammatory Bowel Disease-associated colorectal cancer (IBD-CRC) is a known and serious complication of Inﬂammatory Bowel Disease (IBD) affecting the colon. However, relatively little is known about the pathogenesis of IBD-associated colorectal cancer in comparison with its sporadic cancer counterpart. Here, we investigated the function of Dock2, a gene mutated in ~10% of IBDassociated colorectal cancers that encodes a guanine nucleotide exchange factor (GEF) . Using a genetically engineered mouse model of IBD-CRC, we found that whole body loss of Dock2 increases tumourigenesis via immune dysregulation. Dock2-deﬁcient tumours displayed increased levels of IFNγ-associated genes, including the tryptophan metabolising, immune modulatory enzyme, IDO1, when compared to Dock2-proﬁcient tumours. This phenotype was driven by increased IFNγ-production in T cell populations, which inﬁltrated Dock2-deﬁcient tumours, promoting IDO1 expression in tumour epithelial cells. We show that IDO1 inhibition delays tumourigenesis in Dock2 knockout mice, and we conﬁrm that this pathway is conserved across species as IDO1 expression is elevated in human IBD-CRC and in sporadic CRC cases with mutated DOCK2 . Together, these data demonstrate a previously unidentiﬁed tumour suppressive role of DOCK2 that limits IFNγ-induced IDO1 expression and cancer progression, opening potential |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| new avenues for therapeutic intervention. |  |  |\n|  | Oncogene (2024) 43:3094–3107; [https://doi.org/10.1038/s41388-024-03135-9](https://doi.org/10.1038/s41388-024-03135-9) |  |\n|  |  |  |\n\nINTRODUCTION  \nInﬂammatory Bowel Disease–associated colorectal cancer (IBDCRC) is a long term colonic complication of inﬂammatory Bowel Disease (IBD) [1] . IBD is a complex, chronic disease affecting the gastrointestinal tract, characterised by immune dysregulation as a result of genetic, environmental and microbiotal factors [2], and is generally classiﬁed into two subtypes: Ulcerative Colitis, and Crohn’s Disease. IBD-CRC occurs on a background of colonicinﬂammation, and occurs in younger patients [3], and is associated with increased mortality compared to sporadic colorectal cancer [3, 4], yet its pathogenesis is poorly understood. There is therefore an urgent need to understand IBD-CRC in greater detail.  \nThe mutational spectrum of IBD-CRC is different from sporadic colorectal cancer with alterations in TP53 being the most common driver event and APC and KRAS being mutated at signiﬁcantly lower rates [5–7] . In addition, alterations in the RHO/ RAC signalling pathway are frequently associated with IBD-CRC with exome sequencing studies suggesting a prevalence of 50–70% of tumours having alterations in this pathway [6, 7] . It should be noted however that these data do not imply signiﬁcant mutation, and the functional effects of these mutations are unknown. RAC proteins have a critical role in several cellular  \nprocesses including migration, apoptosis, proliferation, and invasion [8–11] but their role in the etiology of IBD-CRC is poorly understood.  \nOf particular interest are mutations in the dedicator of cytokinesis 2 (DOCK2) gene, which have been found in ~10% of IBD-CRC cases [6, 7] . DOCK2 is a 212 kDa protein expressed in both human and mouse, found mainly in peripheral blood ce","cbCaijJfVJc7zkh1","https://ap.wps.com/l/cbCaijJfVJc7zkh1","pdf",8152611,14,"English","# Introduction\n## Background of IBD-CRC and knowledge gaps\n## Genomic landscape and relevance to immune signaling\n## Focus on DOCK2 and immune regulation","[{\"question\":\"What is the main finding about DOCK2 in IBD-associated colorectal cancer?\",\"answer\":\"Whole-body loss of Dock2 increases tumorigenesis by causing immune dysregulation in a DSS-induced IBD-CRC mouse model.\"},{\"question\":\"How does Dock2 deficiency affect IFNγ and IDO1 expression?\",\"answer\":\"Dock2-deficient tumors show increased IFNγ-associated gene expression, including elevated IDO1, alongside increased tryptophan metabolism.\"},{\"question\":\"What role do T cells play in the Dock2-related pathway?\",\"answer\":\"Dock2 loss is linked to increased IFNγ production in T-cell populations that infiltrate tumors, promoting IDO1 expression in tumor epithelial cells.\"}]","Loss of DOCK2 potentiates Inflammatory Bowel Disease–associated colorectal cancer via immune dysfunction and IFNγ induction of IDO1 expression | PDF",1790035252,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc9b071f63a7f03372d9266a3b6d5a4d.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7f3286b6c5810d79cdaf1bef4cdc845a.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/30d06e768dcbfc510038a943a1dedff9.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2f92f7d9c5fb23a74ddf0fa93a69490d.webp",980,1301]